Current oncology最新文献

{"title":"Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations.","authors":"Mariem Galuia, Julia Fedorova, Wassim McHayleh, Eleftherios Mamounas, Sarfraz Ahmad, Sabrina Pavri","doi":"10.3390/curroncol32030154","DOIUrl":"10.3390/curroncol32030154","url":null,"abstract":"<p><p>Breast cancer accounts for about 30% of all new female cancers each year, and its incidence is increasing 0.6% per year. An enhanced understanding of the molecular mechanisms of carcinogenesis has led to the development of constantly evolving strategies for local and systemic therapies. Perioperative chemotherapy, immunotherapy, and endocrine therapy play pivotal roles in the overall treatment plan. Guidelines on the appropriate use of these drugs in patients undergoing extirpative breast surgery and/or breast reconstruction are lacking. Clear indications for the management of systemic therapies relative to the timing of surgery is crucial to ensure consistent treatment outcomes and to minimize complications. Our purpose is to propose evidence-based recommendations to optimize the perioperative management of systemic therapies in patients undergoing breast cancer surgery and breast reconstructive surgery. In this review, we outline the basic tenets of breast cancer therapies, provide an overview on wound-healing principles, delineate relevant pharmacodynamic concepts, summarize literature and pharmacologic data from various preclinical studies and clinical trials, and propose treatment recommendations. Synopsis: This review proposes evidence-based recommendations regarding systemic therapies management for outcome optimization in the perioperative period in breast cancer patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Detection and Age-Comparative Analysis of Colorectal Cancer Screening: Insights from the Turkish Population.","authors":"Cem Batuhan Ofluoğlu, Fırat Mülküt, İsa Caner Aydın, Mehmet Karahan","doi":"10.3390/curroncol32030153","DOIUrl":"10.3390/curroncol32030153","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the diagnostic yield of colonoscopy in asymptomatic individuals aged 45-49 years compared with those aged 50-54 years in a Turkish population, providing insights into region-specific screening strategies.</p><p><strong>Methods: </strong>This retrospective multicenter study was conducted across three tertiary endoscopy units in Turkey. Screening colonoscopy data from 3943 asymptomatic individuals aged 45-54 years between 2018 and 2023 were analyzed. The patients were stratified into two groups: 45-49 years (Group 1) and 50-54 years (Group 2). Demographic characteristics, polyp size, histological features, and prevalence of early-onset advanced colorectal neoplasia (EAO-aCRN) were assessed.</p><p><strong>Results: </strong>A total of 3943 patients were included, with 862 in Group 1 (45-49 years) and 3081 in Group 2 (50-54 years). The polyp detection rate was 16.6% in Group 1 and 22.9% in Group 2 (<i>p</i> < 0.001). The adenoma detection rates were 10.8% and 13.9% in Groups 1 and 2, respectively (<i>p</i> = 0.018). The advanced polyp detection rates were 3.2% and 7.3% in Groups 1 and 2, respectively (<i>p</i> < 0.001). Mean polyp size was 6.5 ± 5.1 mm in Group 1 and 8.8 ± 8.4 mm in Group 2 (<i>p</i> < 0.001). The mean number of polyps per patient was 1.5 ± 0.8 in Group 1 and 1.9 ± 1.6 in Group 2 (<i>p</i> = 0.023). Advanced neoplasia was detected in 16.6% of Group 1 patients compared with 22.9% of Group 2 patients (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>While CRC screening at age 45 demonstrated lower detection rates of polyps and advanced neoplasia than at age 50, the higher prevalence of EAO-CRN among 45-49-year-olds in Turkey underscores the importance of early screening in high-risk populations. Tailored regional strategies incorporating individual risk factors are crucial for optimizing CRC prevention policies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive Decline in Glioblastoma (GB) Patients with Different Treatment Modalities and Insights on Untreated Cases.","authors":"Keyvan Ghadimi, Imane Abbas, Alireza Karandish, Celina Crisman, Emad N Eskandar, Andrew J Kobets","doi":"10.3390/curroncol32030152","DOIUrl":"10.3390/curroncol32030152","url":null,"abstract":"<p><strong>Background: </strong>Cognitive decline is common in patients with Glioblastoma (GB), occurring in both treated and untreated cases. It frequently presents as impairments in memory, attention, language, or other cognitive functions. In addition, these cognitive deficits can affect quality of life, functional independence, and overall survival, and they are associated with psychiatric conditions such as anxiety and depression.</p><p><strong>Methods: </strong>This narrative review evaluates cognitive deficits in GB patients, both with and without treatment. It also explores the impact of tumor features such as size, location, and histology, along with patient characteristics such as age and education, and discusses the effects of standard therapies, such as surgery, chemotherapy, and radiotherapy, on cognitive outcomes.</p><p><strong>Results: </strong>Cognitive impairment in GB is influenced by tumor- and patient-specific factors, as well as treatment modalities. Initially, combination therapies such as surgery, radiotherapy, and chemotherapy may improve cognitive domains by reducing tumor burden, relieving cerebral edema, and reducing mass effects, subsequently bringing indirect effects of improved mental health and mood. While certain treatments like radiotherapy and chemotherapy carry risks of delayed neurotoxicity, studies indicate that, on balance, treated patients generally show better preservation or improvement in cognitive function than those who go untreated. However, excessive treatment aggressiveness and cumulative neurotoxic effects may diminish cognitive benefits.</p><p><strong>Conclusion: </strong>Cognitive function is an independent factor in GB, which could affect survival in GB patients, therefore making routine cognitive assessments essential for prognosis, treatment planning, and rehabilitation. Neuroprotective agents, cognitive rehabilitation, and personalized, multidisciplinary strategies can help optimize both survival and cognitive preservation.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US.","authors":"Divyan Chopra, David M Waterhouse, Ihtisham Sultan, Björn Stollenwerk","doi":"10.3390/curroncol32030151","DOIUrl":"10.3390/curroncol32030151","url":null,"abstract":"<p><p>This study characterizes real-world treatment patterns and economic and healthcare resource utilization (HCRU) burden associated with first-line (1L) treatment of metastatic non-small cell lung cancer (NSCLC) without actionable alterations in the United States. This retrospective observational study used Optum Clinformatics^® data. A total of 15,659 patients with metastatic NSCLC who started 1L treatment between January 2020 and March 2023 were included (52% male; mean age at the start of 1L treatment 71.7 years; 86% Medicare Advantage). The most frequent 1L regimens were immune checkpoint inhibitor (ICI) + platinum-based chemotherapy (PBCT) (47%), PBCT only (26%), and ICI only (20%). The median 1L treatment duration was 4.2 months (range 2.7-6.5) and was shorter with chemotherapy-only regimens. Outpatient visits accounted for the majority of HCRU (mean 6.6 visits per patient per month [PPPM]). Outpatient, inpatient, and emergency department visits were highest for chemotherapy-only regimens. Mean total (all-cause) healthcare costs were $32,215 PPPM and were highest for ICI + chemotherapy ($34,741-38,454 PPPM). Inpatient costs PPPM were highest for PBCT ($4725) and ICI + non-PBCT ($4648). First-line treatment of metastatic NSCLC without actionable alterations imposes a notable HCRU and cost burden, underscoring the need for better treatment options to improve outcomes and reduce economic impact.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.","authors":"Yan Xiang, Meiling Zhang, Qian Wang, Jingwen Liu, Lulin Zeng, Ao Sun, Kaihua Lu","doi":"10.3390/curroncol32030148","DOIUrl":"10.3390/curroncol32030148","url":null,"abstract":"<p><p><b>Background:</b> HER2 mutations are rare driver events in advanced NSCLC, with limited relief from current targeted therapies. This study aimed to characterize the molecular features of HER2-mutant NSCLC and to evaluate the clinical efficacy of pyrotinib-based combination therapy as a first-line treatment, providing evidence for optimizing treatment strategies. <b>Methods:</b> NSCLC patients diagnosed at Jiangsu Province People's Hospital from 2016 to 2024 were enrolled. HER2-positive cases were screened by IHC/FISH and further profiled by NGS. Treatment response was assessed by RECIST 1.1, and survival analysis was performed using Kaplan-Meier and log-rank tests. <b>Results:</b> Among 144 HER2-mutant NSCLC cases confirmed by NGS, 10 insertion mutations, 26 missense mutations, and 2 fusion mutations were identified. The most common mutation was the exon 20 p.A775_G776insYVMA (47.9%), and TP53 was the most frequent co-mutation (10.4%). In terms of efficacy, the pyrotinib-based combination therapy demonstrated significant clinical benefit, with an ORR of 33.3%, DCR of 95.2%, median PFS (mPFS) of 11.3 months (95% CI: 10.27-12.26), and median OS (mOS) of 21.0 months (95% CI: 18.00-23.94). Subgroup analysis revealed no significant impact of mutation subtype or co-mutation status on the treatment efficacy, but patients with brain metastases had a significantly worse prognosis than those without metastasis (mPFS: 5.1 vs. 12.9 months, <i>p</i> < 0.01; mOS: 9.3 vs. 26.5 months, <i>p</i> < 0.01). All TRAEs were grade 1-3 (any grade: 90.5%; grade 3: 14.3%), with the most common TRAE being diarrhea (any grade: 85.7%; grade 3: 9.5%). <b>Conclusions:</b> Pyrotinib-based combination therapy is a feasible first-line treatment for HER2-mutant NSCLC, demonstrating significant survival benefits and manageable toxicity. However, brain metastasis patients require enhanced comprehensive management.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies.","authors":"Ling Fan, Jintong Na, Tieliu Shi, Yuan Liao","doi":"10.3390/curroncol32030149","DOIUrl":"10.3390/curroncol32030149","url":null,"abstract":"<p><p>Hepatoblastoma (HB) is the most common malignant liver tumor in children under five years of age. Although globally rare, it accounts for a large proportion of liver cancer in children and has poor survival rates in high-risk and metastatic cases. This review discusses the molecular mechanisms, diagnostic methods, and therapeutic strategies of HB. Mutations in the CTNNB1 gene and the activation of the Wnt/β-catenin pathway are essential genetic factors. Furthermore, genetic syndromes like Beckwith-Wiedemann syndrome (BWS) and Familial Adenomatous Polyposis (FAP) considerably heighten the risk of associated conditions. Additionally, epigenetic mechanisms, such as DNA methylation and the influence of non-coding RNAs (ncRNAs), are pivotal drivers of tumor development. Diagnostics include serum biomarkers, immunohistochemistry (IHC), and imaging techniques. Standard treatments are chemotherapy, surgical resection, and liver transplantation (LT). Emerging therapies like immunotherapy and targeted treatments offer hope against chemotherapy resistance. Future research will prioritize personalized medicine, novel biomarkers, and molecular-targeted therapies to improve survival outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Rate Variability Biofeedback Training Can Improve Menopausal Symptoms and Psychological Well-Being in Women with a Diagnosis of Primary Breast Cancer: A Longitudinal Randomized Controlled Trial.","authors":"Karina Dolgilevica, Elizabeth Grunfeld, Nazanin Derakshan","doi":"10.3390/curroncol32030150","DOIUrl":"10.3390/curroncol32030150","url":null,"abstract":"<p><p>Breast cancer survivors experience numerous chronic symptoms linked to autonomic dysfunction including anxiety, stress, insomnia, menopausal symptoms, and cognitive impairment. Effective non-pharmacological solutions to address these are currently lacking.</p><p><strong>Methods: </strong>Our three-armed longitudinal randomized controlled trial assessed the effectiveness of a 4-week remote smartphone-based heart rate variability biofeedback intervention which involved daily paced breathing at 6 breaths p/min; active (12 breaths p/min) and waitlist controls were included. Heart rate variability and self-reported cancer-related symptoms were assessed at baseline, post-, and 6 months-post intervention. Participants were 60 UK-based women with primary breast cancer history (6 to 60 months post-active treatment).</p><p><strong>Results: </strong>The intervention group showed significant increases in low-frequency heart rate variability over time (F (4, 103.89) = 2.862, <i>p</i> = 0.027, <i>d</i> = 0.33), long-lasting improvement in sleep quality (F (4, 88.04) = 4.87, <i>p</i> = 0.001, <i>d</i> = 0.43) and cessations in night sweats (<i>X</i>² (2, <i>N</i> = 59) = 6.44, <i>p</i> = 0.04, Cramer's V = 0.33), and reduced anxiety post-intervention compared to the active and waitlist controls (F (4, 82.51) = 2.99, <i>p</i> = 0.023, <i>d</i> = 0.44). Other findings indicated that the intervention and active control participants reported lasting improvements in cognitive function, fatigue, and stress-related symptoms (all <i>ps</i> < 0.05). The waitlist group reported no symptom changes across time.</p><p><strong>Conclusion: </strong>Heart rate variability biofeedback is a feasible intervention for addressing diverse chronic symptoms commonly reported by breast cancer survivors.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Pandemic Impact on Delays in Diagnosis and Treatment for Cervical Cancer in Montreal, Canada.","authors":"Yohan Kerbage, Elise Hillmann, Jessica Ruel-Laliberté, Vanessa Samouelian","doi":"10.3390/curroncol32030147","DOIUrl":"10.3390/curroncol32030147","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic has been responsible for a major reorganization of healthcare systems, with less access for cancer screening. Few data exist on the impact of cervical cancer treatment during the pandemic.</p><p><strong>Methods: </strong>The purpose of this study was to compare the cervical cancer stage at diagnosis and the surgical and medical treatment delays before and during the COVID-19 pandemic. This is a retrospective cohort study of all cervical cancers diagnosed at any stages between 1 January 2018 and 28 February 2022 at the Centre Hospitalier de l'Université de Montréal. Stage at diagnosis, time to initial referral, time from diagnosis to treatment before and during the COVID-19 pandemic were compared.</p><p><strong>Results: </strong>A total of 244 cervical cancers were diagnosed during the study period. No differences were observed between the number of cases diagnosed before and after pandemic (<i>p</i> = 0.237). Most patients and disease characteristics did not differ between the study periods, but the patients were significantly younger (<i>p</i> = 0.007), with higher BMI (<i>p</i> = 0.024) in the pandemic period. The mean time between initial diagnosis and referral was longer during the pandemic by 13 days (<i>p</i> = 0.042). The mean time between diagnosis and MRI and diagnosis and PET CT was not longer during the pandemic (<i>p</i> = 0.481 and <i>p</i> = 0.384). There were no significant differences in the mean time from the initial referring to the first visit at the CHUM (<i>p</i> = 0.895) or in the mean time from diagnosis to treatment (0.668) and duration of treatment (<i>p</i> = 0.181) Conclusion. Minor delays were observed during the COVID-19 pandemic. Cervical cancer patients treated at the CHUM, a tertiary and quaternary Canadian public health center, were globally referred and treated similarly, as those who were treated before pandemic.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer: Targeted Therapy in 2025.","authors":"Nicole Bouchard, Nathalie Daaboul","doi":"10.3390/curroncol32030146","DOIUrl":"10.3390/curroncol32030146","url":null,"abstract":"<p><p>Lung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer (NSCLC) actionable genomic alterations (AGA). AGAs are mostly found in lung adenocarcinomas, a subtype of non-small cell lung cancers. We will focus on the current treatment for EGFR mutations, ALK fusions, ROS1 fusions, BRAF V600E mutations, MET exon 14-skipping mutations, RET fusions, KRAS G12C mutations, ERBB2 mutations (also called HER2 mutations), and NTRK fusions. We will also touch on the key toxicities associated with these medications. Treatments are mostly available for the metastatic stage, but we will also discuss adjuvant therapy for EGFR mutations and ALK fusions, as well as stage III post-chemoradiotherapy treatment for EGFR lung cancer.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Extent to Which Artificial Intelligence Can Help Fulfill Metastatic Breast Cancer Patient Healthcare Needs: A Mixed-Methods Study.","authors":"Yvonne W Leung, Jeremiah So, Avneet Sidhu, Veenaajaa Asokan, Mathew Gancarz, Vishrut Bharatkumar Gajjar, Ankita Patel, Janice M Li, Denis Kwok, Michelle B Nadler, Danielle Cuthbert, Philippe L Benard, Vikaash Kumar, Terry Cheng, Janet Papadakos, Tina Papadakos, Tran Truong, Mike Lovas, Jiahui Wong","doi":"10.3390/curroncol32030145","DOIUrl":"10.3390/curroncol32030145","url":null,"abstract":"<p><p>The Artificial Intelligence Patient Librarian (AIPL) was designed to meet the psychosocial and supportive care needs of Metastatic Breast Cancer (MBC) patients with HR+/HER2- subtypes. AIPL provides conversational patient education, answers user questions, and offers tailored online resource recommendations. This study, conducted in three phases, assessed AIPL's impact on patients' ability to manage their advanced disease. In Phase 1, educational content was adapted for chatbot delivery, and over 100 credible online resources were annotated using a Convolutional Neural Network (CNN) to drive recommendations. Phase 2 involved 42 participants who completed pre- and post-surveys after using AIPL for two weeks. The surveys measured patient activation using the Patient Activation Measure (PAM) tool and evaluated user experience with the System Usability Scale (SUS). Phase 3 included focus groups to explore user experiences in depth. Of the 42 participants, 36 completed the study, with 10 participating in focus groups. Most participants were aged 40-64. PAM scores showed no significant differences between pre-survey (mean = 59.33, SD = 5.19) and post-survey (mean = 59.22, SD = 6.16), while SUS scores indicated good usability. Thematic analysis revealed four key themes: AIPL offers basic wellness and health guidance, provides limited support for managing relationships, offers limited condition-specific medical information, and is unable to offer hope to patients. Despite showing no impact on the PAM, possibly due to high baseline activation, AIPL demonstrated good usability and met basic information needs, particularly for newly diagnosed MBC patients. Future iterations will incorporate a large language model (LLM) to provide more comprehensive and personalized assistance.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}